Risk Factors for Intraoperative Hypoglycemia in Children: A Multicenter Retrospective Cohort Study

Lori Q Riegger1, Aleda M Leis, Kristine H Golmirzaie

  • 1From the Department of Anesthesiology, University of Michigan Health System, Ann Arbor, Michigan.

Insights

Young children, especially those under five or weighing less than 20 kg, are at higher risk for intraoperative hypoglycemia. Specific risk factors include prematurity, poor feeding, and certain surgical procedures.

Area of Science:

  • Pediatric Anesthesiology
  • Critical Care Medicine
  • Clinical Risk Management

Background:

  • Intraoperative hypoglycemia poses a significant risk of neurological damage in children.
  • Limited research exists on identifying specific risk factors for this condition.

Purpose of the Study:

  • To identify independent risk factors for intraoperative hypoglycemia in pediatric patients.
  • To characterize the patient population experiencing intraoperative hypoglycemia.

Main Methods:

  • Retrospective analysis of anesthetic records from 12 institutions (2012-2016).
  • Inclusion of patients under 18 years old.
  • Multivariable logistic regression to determine predictors of blood glucose <60 mg/dL.

Main Results:

  • Hypoglycemia (blood glucose <60 mg/dL) occurred in 3.9% of cases with glucose monitoring.
  • Key predictors included young age (<5 years), low weight-for-age, American Society of Anesthesiologists (ASA) status ≥III, presence of gastric/jejunal tubes, poor feeding, and abdominal surgery.
  • 80% of hypoglycemia cases involved children under 5 years or weighing less than 20 kg.

Conclusions:

  • Young age, specific comorbidities, and surgical factors are significant risk factors for intraoperative hypoglycemia in children.
  • Close blood glucose monitoring is crucial for high-risk pediatric surgical patients.
Abstract

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
688
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
4.1K
Pathophysiology of Diabetes01:20

Pathophysiology of Diabetes

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
2.9K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
482
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
553
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
513